Skip to main
RAPP

RAPP Stock Forecast & Price Target

RAPP Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Rapport Therapeutics is a clinical-stage biotechnology company focused on the development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's lead asset RAP-219, an AMPA modulator that selectively targets TARPγ8, is currently in development for focal onset epilepsy, generalized epilepsy, and bipolar mania. The company's portfolio also includes two discovery-stage nicotinic acetylcholine receptor programs for the treatment of chronic pain and hearing disorders. With a long half-life and potential to address the kindling effect of repeated episodes in both epilepsy and mania, RAP-219 presents a strong opportunity for addressing relapse and filling a gap in the current treatment landscape for patients with bipolar disorder. Additionally, the company has a solid financial outlook, with a projected peak sales of $3.3B for RAP-219.

Bears say

Rapport Therapeutics is a clinical-stage biotechnology company developing small molecule medications for neurological and psychiatric conditions. However, with stiff competition in the epilepsy and manic bipolar markets and dependence on third-party suppliers for production, there are significant commercial and manufacturing risks for the company. While its lead asset RAP-219 has potential, there is no guarantee of market share success and potential delays in clinical trials.

RAPP has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Rapport Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Rapport Therapeutics Inc (RAPP) Forecast

Analysts have given RAPP a Buy based on their latest research and market trends.

According to 6 analysts, RAPP has a Buy consensus rating as of Aug 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $60.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $60.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Rapport Therapeutics Inc (RAPP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.